Eye care services provider Dr Agarwal's Health Care, which is set to launch its ₹3,027 crore IPO this week, plan to merge its listed subsidiary, Dr Agarwal Eye Hospital, with the parent company post listing. In an interaction with Fortune India, Dr. Adil Agarwal, a Whole-time Director and the CEO of the company, shared his views on the IPO decision, how fundraising will help in debt reduction, and explained how India’s eye care market faces a huge challenge of bridging the deficit of optometrists.

Backed by private equity firms TPG and Temase, Dr. Agarwal's Health Care looks to raise ₹3,027 crore at a market value of ₹12,698 crore at the upper end of the price band of ₹382 to ₹402 per equity share. The three-day IPO will open for subscription on January 29, 2025, while the tentative date for listing of the stock on the BSE and NSE is February 5, 2025.